Cefmetazole

ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Cefmetazole is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1989. DrugCentral lists 3 molecular targets, including IDE, pbpA and mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB. Recorded indications include Haemophilus influenzae pneumonia, Infection of skin AND/OR subcutaneous tissue, Infectious disease of abdomen and Lower respiratory tract infection.

• Approval status: ofm (first approved 1989 by the FDA).
• Molecular targets: IDE, pbpA and mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB (3 listed in DrugCentral).
• Indications: Haemophilus influenzae pneumonia, Infection of skin AND/OR subcutaneous tissue, Infectious disease of abdomen, Lower respiratory tract infection and Pneumonia and others.
• ATC code: J01DC09 (Second-generation cephalosporins).
• Molecular formula: C15H17N7O5S3; molecular weight 471.53 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (10)

• Haemophilus influenzae pneumonia
• Infection of skin AND/OR subcutaneous tissue
• Infectious disease of abdomen
• Lower respiratory tract infection
• Pneumonia
• Pneumonia due to Escherichia coli
• Pneumonia due to Streptococcus
• Prevention of Perioperative Infection
• Staphylococcal pneumonia
• Urinary tract infectious disease

Mechanism & targets

Molecular targets (3)

Target	Gene	Action	Activity
Insulin-degrading enzyme	IDE	unknown	IC50 5.16
Penicillin-binding protein 1A	pbpA	unknown	—
Bacterial penicillin-binding protein	mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1989-12-11	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
J01DC09	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Second-generation cephalosporins

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Intrauterine infection	59.0
Hepatic function abnormal	44.2

Chemical structure

• Molecular formula: C₁₅H₁₇N₇O₅S₃
• Molecular weight: 471.53 g/mol
• CAS number: 56796-20-4
• InChIKey: SNBUBQHDYVFSQF-HIFRSBDPSA-N
• PubChem CID: 42008

CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cefmetazole used for?

DrugCentral lists the following indications for Cefmetazole: Haemophilus influenzae pneumonia, Infection of skin AND/OR subcutaneous tissue, Infectious disease of abdomen, Lower respiratory tract infection, Pneumonia, Pneumonia due to Escherichia coli, Pneumonia due to Streptococcus and Prevention of Perioperative Infection and others.

How does Cefmetazole work?

Its molecular targets in DrugCentral include IDE, pbpA and mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB (inhibitor).

When was Cefmetazole first approved?

Cefmetazole was first approved by the FDA in 1989.

What is the chemical formula of Cefmetazole?

Cefmetazole has the molecular formula C15H17N7O5S3 and a molecular weight of 471.53 g/mol.

Sources

• DrugCentral drug card 539 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201118 — compound record and bioactivity
• PubChem CID 42008 — chemical identifiers
• DrugBank DB00274 — drug record
• FDA UNII 3J962UJT8H — substance identity
• DailyMed: FDA labels for Cefmetazole — current prescribing information (label search)
• UniProt P14735 (IDE) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.